Table 4.
Biological Activities of Compounds 1–5 and 7–12
| Cancer cell line |
Infectious microorganism |
|||||
|---|---|---|---|---|---|---|
| (% Growth)a |
(IC50 μM)b |
|||||
| Compound | DU-145 | A2058 | DU-145 | A2058 | P. falciparum c | M. tuberculosis d |
| 1 | 92 | 86 | >10 | >10 | 4 | 62 |
| 2 | 112 | 106 | >10 | >10 | >10 | 71 |
| 3 | 31 | 23 | 4 | 3 | 0.3 | N.T.e |
| 4 | 15 | 51 | 1 | >10 | 3 | 92 |
| 5 | 62 | 71 | >10 | >10 | >10 | 59 |
| 7 | 38 | 69 | 8 | >10 | >10 | N.T.e |
| 8 | 81 | 79 | >10 | >10 | >10 | N.T.e |
| 9 | 102 | 60 | >10 | >10 | >10 | 30 |
| 10 | 79 | 75 | 24 | 24 | 0.6 | 13 |
| 11 | 13 | 8 | 2 | 0.8 | 0.3 | 68 |
| 12 | 95 | 81 | >10 | >10 | 7 | N.T.e |
| +Ctrl | – | – | – | – | 0.09 | 0.05 |
a
DU-145 prostate cancer and A2058 melanoma cells (5,000 cells/well, 96 well plates) were treated with compounds at 10μM for 48 h.
b
Cells were treated with compounds in a dose-dependent manner for 48 h. Then, the MTS assays assessed cell viability. Experiments in quadruplicate.
c
Chloroquine-resistant (CQ-R) W2 strains. IC50 in μg/mL. Chloroquine was used as a positive control.
d
Mtb H37Rv strain. Minimum inhibitory concentrations (MIC) in μg/mL. Rifampin was used as a positive control.
e
N.T. = Not tested.